康缘药业(600557.SH)：收到车前子片临床试验批准通知书

Core Insights - Kangyuan Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Cheqianzi Tablets, which are intended for the treatment of diabetic kidney disease (DKD) with a focus on damp-heat syndrome [1][2] - Preclinical studies indicate that Cheqianzi Tablets show significant therapeutic effects on DKD, including reductions in blood glucose, insulin resistance, and various proteinuria markers in diabetic mouse models [1] - The development of Cheqianzi Tablets is expected to fill a gap in the market for traditional Chinese medicine targeting DKD, which currently has limited options [2] Company Summary - Kangyuan Pharmaceutical has announced the approval for clinical trials of Cheqianzi Tablets, which are aimed at treating DKD [1] - The company’s research highlights the safety and efficacy of Cheqianzi Tablets, showing a wide safety margin in toxicological studies [1] Industry Summary - Diabetic kidney disease is a common and severe microvascular complication of diabetes, affecting approximately 20% to 40% of diabetic patients, with an increasing incidence among younger populations [2] - Current clinical treatments for DKD primarily focus on controlling blood pressure, blood sugar, and diet, indicating a need for more targeted therapies [2] - The lack of traditional Chinese medicine options specifically addressing damp-heat syndrome in DKD presents a significant opportunity for Cheqianzi Tablets in the market [2]